Last updated: February 17, 2026
Overview
NDC 44087-1117 is the drug Aflibercept Injection, marketed under the brand name Eylea. It is indicated primarily for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy, and other ocular conditions. The drug is manufactured by Regeneron Pharmaceuticals and has a significant position in ophthalmology treatment.
Market Size and Dynamics
-
Market Volume and Key Indications
- The global ophthalmic drug market was valued at approximately $12 billion in 2022.
- Aflibercept holds an estimated 45% share in wet AMD treatment segments.
- In 2022, U.S. sales for Eylea topped $4.5 billion, representing roughly 40% of Regeneron’s total revenue.
-
Competitors
- Main competitors include Ranibizumab (Lucentis) and Bevacizumab (Off-label use; Avastin).
- Recent entries include biosimilars and newer agents targeting similar pathways.
-
Market Drivers
- Aging population increasing demand for retinal therapies.
- Rising prevalence of diabetes, elevating diabetic retinopathy cases.
- Clinician preference for Eylea due to its dosing schedule and efficacy profile.
-
Geographic Market Trends
- U.S. accounts for approximately 60% of global sales.
- Europe and Japan represent significant secondary markets, with growth expected in Asia-Pacific due to expanding healthcare access.
Pricing and Reimbursement
-
Current Price Point
- The average wholesale price (AWP) for a 2-mL vial of Eylea is around $1,900.
- Actual reimbursement rates, influenced by insurance and cross-national healthcare policies, range from $1,500 to $2,200 per dose in the U.S.
-
Pricing Trends
- No significant price reductions have been implemented since FDA approval in 2011.
- Biosimilar entry remains limited due to patent protections and regulatory hurdles, maintaining pricing stability.
-
Reimbursement Policies
- Medicare Part B reimburses Eylea under the average sales price (ASP) plus 4.3% for outpatient injections.
- Commercial insurers often negotiate discounts, influencing net prices downward.
Future Price Projections
-
Biosimilar Impact
- Biosimilar versions of Eylea are under development; approval timelines are uncertain but could alter pricing dynamics.
- Entry of biosimilars could decrease Eylea prices by 20-35% over the next 3-5 years.
-
Regulatory Changes
- Patent litigation delays have kept biosimilar competition at bay; this may change if litigations resolve favorably for biosimilar developers.
-
Market Penetration and Volume Growth
- Advances in treatment guidelines and increased screening could expand global market volume by 4-6% annually.
- Price stability is likely in the near term, but volume-based growth will influence overall revenue.
-
Price Compression Scenarios
- Moderate Scenario: Prices decline 10-15% over five years, driven by biosimilar competition.
- Aggressive Scenario: 25-35% price reduction within 3-4 years following biosimilar market entry.
Key Takeaways
- The current U.S. wholesale price for Eylea is approximately $1,900 per vial.
- Market size remains robust with stable pricing due to intellectual property protections and a dominant position.
- Biosimilar competition could reduce prices significantly if approvals occur within the next 2-4 years.
- Volume growth driven by demographic trends could sustain revenues despite potential price declines.
- Regulatory and legal factors will influence the speed and extent of market entry by biosimilars.
FAQs
Q1: What is the primary indication for NDC 44087-1117?
A: It treats wet age-related macular degeneration and other retinal conditions that cause visual impairment.
Q2: How does the price of Eylea compare to its main competitor, Lucentis?
A: Eylea's wholesale price is roughly similar, around $1,900 per vial, while Lucentis is approximately $1,850. Reimbursement and dosing frequency influence actual costs.
Q3: When are biosimilars expected to impact the Eylea market?
A: Biosimilar candidates are in development, with approval potential within the next 2-4 years, contingent upon regulatory and legal factors.
Q4: How do reimbursement policies affect Eylea’s pricing?
A: Reimbursement rates, mainly from Medicare and private insurers, influence net prices received by providers, often leading to discounts from list prices.
Q5: What factors could significantly alter future price projections?
A: Biosimilar approval and market entry, regulatory reforms, advances in alternative therapies, and shifts in treatment guidelines are key factors.
Sources:
[1] Regeneron Pharmaceuticals Annual Report 2022
[2] IQVIA Ophthalmic Drug Market Data 2022
[3] Medicare Reimbursement Policy Updates 2023
